1. Scrip
  2. >>COVID-19

Coronavirus Update: FDA Tries To Control J&J’s Vaccine, Extended Use Of Paxlovid

 
• By Scrip Team

The FDA has also moved to limit use of J&J’s COVID-19 vaccine amid reports of rare but dangerous blood clots, while Regeneron highlighted efforts to get approval for REGEN-COV in its Q1 earnings.

In response to reports of some patients taking Pfizer Inc.’s COVID-19 treatment, Paxlovid (nirmatrelvir and ritonavir), experiencing a return of the disease, CEO Albert Bourla advised in a 3 May Bloomberg interview that if that happens, they can take more of the drug. But the US Food and Drug Administration spoke out against the idea.

Bourla suggested in the interview that if patients experience a return of infection after taking a full course of Paxlovid,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.